ReviR Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
ReviR Therapeutics General Information
Description
Developer of RNA therapeutics intended to treat cancer, rare genetic disorders, and infectious diseases. The company develops an artificial intelligence-based and computation-empowered platform to discover RNA-targeting therapeutics, enabling healthcare personnel to deliver transformative therapies for millions of patients.
Contact Information
Website
www.revirtx.comCorporate Office
- 150 North Hill Drive
- Brisbane, CA 94005
- United States
Corporate Office
- 150 North Hill Drive
- Brisbane, CA 94005
- United States
ReviR Therapeutics Timeline
ReviR Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 22-Apr-2026 | Completed | Product Development | |||
| 4. Grant | 20-Nov-2025 | Completed | Product Development | |||
| 3. Early Stage VC (Series A) | 19-Jun-2024 | Completed | Product Development | |||
| 2. Early Stage VC | 17-Jan-2022 | $20M | $20M | Completed | Product Development | |
| 1. Seed Round | 06-May-2021 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ReviR Therapeutics Comparisons
Industry
Financing
Details
ReviR Therapeutics Competitors (6)
One of ReviR Therapeutics’s 6 competitors is Laminar Pharma, a Venture Capital-Backed company based in Palma de Mallorca, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Laminar Pharma | Venture Capital-Backed | Palma de Mallorca, Spain | ||||
| Arrakis Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| Astex Pharmaceuticals | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Moderna | Formerly VC-backed | Cambridge, MA |
ReviR Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ReviR Therapeutics Patents
ReviR Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025245500-A1 | 2-(4-chloro-3-fluorophenoxy)-n-[trans-4-[5-[3-(trifluoromethoxy)-1-azetidinyl]-1,3,4-oxadiazol-2-yl]cyclohexyl]-acetamide for use in the treatment of vanishing white matter, huntington's disease, charcot marie tooth syndrome, amyotrophic lateral sclerosis or for increasing the guanine nucleotide exchange factor activit | Pending | 23-May-2024 | ||
| US-20260315464-A1 | Compositions, methods, and systems for modulating splicing of msh3 | Pending | 06-Jun-2023 | ||
| WO-2024251211-A1 | Compositions, methods, and systems for modulating splicing of msh3 | Inactive | 06-Jun-2023 | ||
| EP-4724441-A1 | Isoindolinone and dihydropyrrolopridinone compounds and uses thereof | Pending | 06-Jun-2023 | ||
| WO-2024251212-A1 | Isoindolinone and dihydropyrrolopridinone compounds and uses thereof | Inactive | 06-Jun-2023 | A61P25/28 |
ReviR Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ReviR Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CureCMT | Venture Capital | Minority | ||
| California Institute for Regenerative Medicine | Government | |||
| CMT Research Foundation | Not-For-Profit Venture Capital | Minority | ||
| Lapam Capital | Venture Capital | Minority | ||
| XtalPi Technology | Corporation | Minority |
ReviR Therapeutics FAQs
-
When was ReviR Therapeutics founded?
ReviR Therapeutics was founded in 2021.
-
Where is ReviR Therapeutics headquartered?
ReviR Therapeutics is headquartered in Brisbane, CA.
-
What is the size of ReviR Therapeutics?
ReviR Therapeutics has 21 total employees.
-
What industry is ReviR Therapeutics in?
ReviR Therapeutics’s primary industry is Drug Discovery.
-
Is ReviR Therapeutics a private or public company?
ReviR Therapeutics is a Private company.
-
What is ReviR Therapeutics’s current revenue?
The current revenue for ReviR Therapeutics is .
-
How much funding has ReviR Therapeutics raised over time?
ReviR Therapeutics has raised $50M.
-
Who are ReviR Therapeutics’s investors?
CureCMT, California Institute for Regenerative Medicine, CMT Research Foundation, Lapam Capital, and XtalPi Technology are 5 of 11 investors who have invested in ReviR Therapeutics.
-
Who are ReviR Therapeutics’s competitors?
Laminar Pharma, Arrakis Therapeutics, Astex Pharmaceuticals, Alnylam Pharmaceuticals, and Moderna are some of the 6 competitors of ReviR Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
